Immune checkpoint inhibitors in sarcomas: a systematic review
Μaria Anastasiou(National and Kapodistrian University of Athens), Amanda Psyrri(National and Kapodistrian University of Athens), Anastasia Kosmidou(National and Kapodistrian University of Athens), Anastasios Kyriazoglou(Alexandra Hospital), Ioannis Kotsantis(National and Kapodistrian University of Athens), Myrto Moutafi(University General Hospital Attikon), Maria Kyrkasiadou(National and Kapodistrian University of Athens), D. Smerdi(National and Kapodistrian University of Athens), Panagiota Economopoulou(National and Kapodistrian University of Athens), Anastasia E. Giannopoulou(National and Kapodistrian University of Athens), Niki Gavrielatou(National and Kapodistrian University of Athens)
Cited by 21
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
|Laboratory Investigation|2022|141
Activation of Wnt Signaling Pathway by Human Papillomavirus E6 and E7 Oncogenes in HPV16-Positive Oropharyngeal Squamous Carcinoma Cells
|Molecular Cancer Research|2010|120